Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07420-9Source: DataRank Database

Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death is a research paper published in Breast Cancer Research and Treatment (2024). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.96)OA: hybridTopics (51)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Yvonne Ziegler ORCID,Blake N. Plotner,Kristen M. Flatt ORCID,Sung Hoon Kim ORCID,John A. Katzenellenbogen ORCID

Live enrichment

PubMed:38980505 PMC:PMC11455716 OpenAlex:https://openalex.org/W4400473315

Breast Cancer Research Foundation

Grant: BCRF-083

NIH/NCI

Grant: 1R01 CA220284

NIH

Grant: R01CA234025

NCI NIH HHS

Grant: R01 CA220284

National Institutes of Health

Grant: 5R01CA234025-03

Impact of cholesterol and its metabolites on breast cancer progression

National Institutes of Health

Grant: 6R01CA220284-05

Chemical, structural and molecular rules for fully antagonizing the estrogen receptor

The Julius and Mary Landfield Cancer Research Fund

FWCI

0.96

Citation Percentile

0.7%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s10549-024-07420-9.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s10549-024-07420-9.pdf

publisherhttps://link.springer.com/article/10.1007/s10549-024-07420-9/fulltext.html

journalhttps://doi.org/10.1007/s10549-024-07420-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38980505

Fields of Study

FOXO transcription factor regulationFerroptosis and cancer prognosisCancer Mechanisms and Therapy0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Forkhead Box Protein M1FerroptosisBreast NeoplasmsCell MovementCell SurvivalFemaleHumansMitochondriaGene Expression Regulation, NeoplasticApoptosisDrug Resistance, NeoplasmArtemisininsCell Line, TumorCell Proliferation

Keywords

FOXM1Cancer researchProgrammed cell deathCancer cellViability assayBiologyApoptosisBreast cancerCell growthCancerCell cycleBiochemistryGeneticsDrug resistanceProliferationEstrogen receptorGene ExpressionFerroptosisCell SurvivalResearchForkhead Box Protein M1Breast NeoplasmsArtemisininsMitochondriaGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmCell MovementCell Line, TumorHumansFemaleCell Proliferation

Sustainable Development Goals

SDG 0: Good health and well-being